Knowledge Hub

Information you can trust.

Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.

FormatAll Articles Booklets Videos Tools External

TopicAll Understanding NET cancer Living with NETs Patient stories NET resources Resources for HCPs What's on

Clear all filters

48 resources

Page 1 of 2

Resources for HCPs
GP Education
Earn RNZCGP CPD points – a free RNZCGP-endorsed online course on identifying and managing neuroendocrine cancer in general practice.
Read
Understanding NET cancer20 Mar 2026
Types of scans for NET Cancers
There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.

Read

Understanding NET cancer20 Mar 2026

Grades of Neuroendocrine (NET) Cancers

What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.

Read

Understanding NET cancer20 Mar 2026

Types of Neuroendocrine Tumours

Neuroendocrine Tumours (NETs) is an umbrella name for a number of different types of tumours, which can arise in different areas of the body. It can be…

Read

Understanding NET cancer16 Mar 2026

Treatments for NETs

Treatments for neuroendocrine cancers vary from person to person and may be one or more of the options listed below.

Read

Resources for HCPs16 Mar 2026

NET Nurse Education Workshops

Supporting nurse participants to understand NETs treatments, management and latest developments in research.

Read

Resources for HCPs16 Mar 2026

In-Service Training

Custom training for nurses – we'll work with you to design a session tailored to your team's NETs care needs.

Read

Understanding NET cancer12 Mar 2026

A second PRRT in the FDA pipeline: 177Lu-edotreotide decision due August 2026

The FDA is expected to decide on ITM-11 (177Lu-edotreotide) for GEP-NETs by 28 August 2026, based on the Phase 3 COMPETE trial results.

Read

Living with NETs11 Mar 2026

Nutrition for NETs

Focusing on diet and healthy eating is important for people living with NETs

Read

Living with NETs11 Mar 2026

Identifying what matters to you

Practical guide to advance care planning – conversations and documents that record what matters most to you and your whānau.

Read

What's on11 Mar 2026

Neuroendocrine Cancer New Zealand is dedicated to providing ongoing patient education.

Our monthly Zoom-In sessions with guest experts cover a vast array of topics of interest to neuroendocrine cancer patients, carers and healthcare…

Read

Living with NETs28 Jan 2026

Living with NETS - Online

Living with NETs is a free online education programme designed for patients and support people navigating life with neuroendocrine tumors, whether you are…

Read

Understanding NET cancer20 Jan 2026

Early signals from alpha-emitter PRRT in SSTR2-positive NETs

A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.

Read

Understanding NET cancer20 Jan 2026

Understanding Neuroendocrine

Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.

Read

What's on19 Jan 2026

Annual Patient Education Day

Our annual Patient Education Day is designed specifically for people living with Neuroendocrine Cancer (NETs), as well as their whānau, friends, and…

Read

What's on19 Jan 2026

Peer Support Catch-Ups

We connect people living with neuroendocrine cancer through local and online peer-support catch-ups, creating a welcoming space to share experiences,…

Read

News2 Jun 2025

Honouring a legacy: Malcolm Legget MNZM

Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.

Read

News15 Apr 2025

Waikato clinicians publish rare renal NET case in international oncology journal

A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.

Read

News12 Apr 2025

Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging

Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.

Read

Understanding NET cancer26 Mar 2025

Cabozantinib approved by the FDA for previously treated advanced NETs

The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.

Read